{"pmcid": "PMC11730665", "article_title": "Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis", "ground_truth": ["rs1799853", "rs4664443", "rs7754840", "rs3765467", "rs2285676", "rs2909451", "rs6923761", "rs163184"], "response": "```json\n[\n  \"rs2909451\",\n  \"rs4664443\",\n  \"rs6923761\",\n  \"rs3765467\",\n  \"rs163184\",\n  \"rs2285676\",\n  \"rs7754840\",\n  \"rs756992\",\n  \"rs1799853\",\n  \"rs1057910\",\n  \"rs57803087\",\n  \"rs4244285\",\n  \"rs4986893\",\n  \"CYP2C9*2\",\n  \"CYP2C9*3\",\n  \"CYP2C19*2\",\n  \"CYP2C19*3\"\n]\n```", "had_paper_context": true, "model": "anthropic/claude-sonnet-4-5-20250929"}
{"pmcid": "PMC12080641", "article_title": "Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank", "ground_truth": ["CYP2C19 ultrarapid metabolizer", "CYP2C19 poor metabolizer", "CYP2C19 intermediate metabolizer"], "response": "```json\n[\n  \"CYP2C19 poor metabolizer\",\n  \"CYP2C19 intermediate metabolizer\",\n  \"CYP2C19 normal metabolizer\",\n  \"CYP2C19 rapid metabolizer\",\n  \"CYP2C19 ultra-rapid metabolizer\"\n]\n```", "had_paper_context": true, "model": "anthropic/claude-sonnet-4-5-20250929"}
{"pmcid": "PMC6347826", "article_title": "Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes", "ground_truth": ["rs7903146"], "response": "```json\n[\n  \"rs7903146\"\n]\n```", "had_paper_context": true, "model": "anthropic/claude-sonnet-4-5-20250929"}
{"pmcid": "PMC11921366", "article_title": "Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report", "ground_truth": ["rs1411200130"], "response": "```json\n[]\n```", "had_paper_context": true, "model": "anthropic/claude-sonnet-4-5-20250929"}
{"pmcid": "PMC7655626", "article_title": "Pharmacogenetic Interactions of Rifapentine plus Isoniazid with Efavirenz or Nevirapine", "ground_truth": ["NAT2 slow acetylator", "CYP2B6 poor metabolizer"], "response": "```json\n[\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs3745274\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs28399499\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4803419\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1801280\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1799930\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1799931\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1801279\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs3732360\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs11045819\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs11045872\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4149032\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4688040\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4646244\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs2071197\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs776746\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4363657\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4149081\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs11045879\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1208\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4271002\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs10841753\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs7643645\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs887829\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs4149056\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1799929\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1041983\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs2291075\"\n  },\n  {\n    \"type\": \"rsID\",\n    \"variant\": \"rs1523130\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"NAT2*5\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"NAT2*6\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"NAT2*7\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"NAT2*14\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"CYP2B6*6\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"CYP2B6*4\"\n  },\n  {\n    \"type\": \"star_allele\",\n    \"variant\": \"CYP2B6*22\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"NAT2 slow acetylator\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"NAT2 intermediate acetylator\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"NAT2 rapid acetylator\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"CYP2B6 poor metabolizer\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"CYP2B6 intermediate metabolizer\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"CYP2B6 normal metabolizer\"\n  },\n  {\n    \"type\": \"metabolizer_phenotype\",\n    \"variant\": \"CYP2B6 rapid metabolizer\"\n  }\n]\n```", "had_paper_context": true, "model": "anthropic/claude-sonnet-4-5-20250929"}
